Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2009
04/15/2009EP2046325A1 Phytoestrogenic formulations and uses thereof
04/15/2009EP2046324A2 Treatment and prevention mucositis by anthocyanidin derivatives
04/15/2009EP2046323A2 Methods, compositions and articles of manufacture for contributing to the treatment of cancers
04/15/2009EP2046322A2 Aryl vinyl sulfides, sulfones, sulfoxides and sulfonamides, derivatives thereof and therapeutic uses thereof
04/15/2009EP2046321A2 Pharmaceutical composition containing bicalutamide and a method for its use
04/15/2009EP2046320A2 Anticonvulsive pharmaceutical compositions
04/15/2009EP2046319A2 Cholecystokinin-1 (cck1) receptor antagonists in the treatment of gastrointestinal and related disorders
04/15/2009EP2046318A1 Combination of adapalene and benzoyl peroxide for treating acne lesions
04/15/2009EP2046317A2 Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives
04/15/2009EP2046316A1 Antiviral use of cationic surfactant
04/15/2009EP2046315A2 Therapeutic agents for the treatment of lymphoid malignancies
04/15/2009EP2046314A2 Polycyclic dianthraquinones as inhibitors of inflammatory cytokines
04/15/2009EP2046313A1 The use of naphtoquinones in the treatment and control of diabetes, insulin resistance and hyperglycemia
04/15/2009EP2046312A2 Pharmaceutical and nutraceutical products comprising vitamin k2
04/15/2009EP2046311A2 Dioxo-alkanes and dioxo-alkenes
04/15/2009EP2046310A2 Treatment and prevention of excessive scarring
04/15/2009EP2046309A2 Use of vitamin d3 agonist in a mammalian model for atopic diseases and of vitamin d3 antagonists for the treatment of atopic diseases
04/15/2009EP2046308A2 Retinoids and small molecules as nrf2 antagonists for use in the treatment of diseases associated with abnormal cell proliferation
04/15/2009EP2046305A2 Pharmaceutical composition for the oral administration of omega polyenoic fatty acids
04/15/2009EP2046303A1 Pharmaceutical compositions comprising a combination of piperidinoalkanol and decongestant
04/15/2009EP2046301A2 Pharmaceutical compositions of active substances difficult to improperly divert from their intended route of administration
04/15/2009EP2046299A1 Controlled-release formulations
04/15/2009EP2046298A1 Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
04/15/2009EP2046297A2 Preparation of pharmaceutical formulations
04/15/2009EP2046296A2 Processes for preparing pharmaceutical compositions
04/15/2009EP2046295A1 Preparation of pharmaceutical compositions
04/15/2009EP2046292A2 Formulations for benzimidazolyl pyridyl ethers
04/15/2009EP2046291A1 Pharmaceutical suspensions comprising phenylephrine and method of preparation
04/15/2009EP2046289A2 Compositions and kits useful for treatment of respiratory illness
04/15/2009EP2046285A1 Granule and orally disintegrating tablet comprising oxycodone
04/15/2009EP2046266A2 End-modified poly(beta-amino esters) and uses thereof
04/15/2009EP2046135A2 Polyphenol/peptide composition and use thereof for promoting gastric health
04/15/2009EP2046122A2 Heme oxygenase inhibitors and methods of therapeutic use
04/15/2009EP2046121A2 Fatty acid pharmaceutical foam
04/15/2009EP2046119A2 Treatment of psychiatric disorders
04/15/2009EP2003130A9 Novel pyridine derivative having anti-helicobacter pylori activity
04/15/2009EP2002840A9 Method for treating oncological diseases
04/15/2009EP1937227B1 Transdermal therapeutic system for administering lipophilic and/or cutaneous low-permeable active substances
04/15/2009EP1896021B1 Solid pharmaceutical preparation containing (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chroman
04/15/2009EP1885336B1 Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
04/15/2009EP1863471B1 Use of angelic acid esters as an antiphlogistic active ingredient and antiphlogistic preparations
04/15/2009EP1861092A4 Potassium channel opener having benzofuroindole skeleton
04/15/2009EP1812430B1 Substituted phenylaminothiazoles and use thereof
04/15/2009EP1809630B1 4-amino-5-oxo-8-phenyl-5h-pyrido-[2,3-d]-pyrimidine derivatives as tyrosine kinase and raf kinase inhibitors for the treatment of tumours
04/15/2009EP1797881B1 Medicinal composition with improved stability and reduced gelation properties
04/15/2009EP1794148B1 Novel phthalazinone derivatives, as aurora-a kinase inhibitors
04/15/2009EP1747220B1 Substituted 1h-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase i epsilon
04/15/2009EP1729732B1 Anionic hydrogel matrices with ph dependent modified release as drug carriers
04/15/2009EP1725235B1 Piperidine derivatives useful as ccr3 antagonists
04/15/2009EP1720994B1 Oligosaccharides, preparation method and use thereof, and pharmaceutical compositions containing same
04/15/2009EP1720550B1 Derivatives of piperidinylalkylcarbamates, preparation method thereof and use of same as faah enzyme inhibitors
04/15/2009EP1719773B1 Fused heterotetracyclic compounds and use tehreof as hcv polymerase inhibitor
04/15/2009EP1711470B1 Malonamide derivatives blocking the activtiy of gamma-secretase
04/15/2009EP1703909B1 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
04/15/2009EP1689720B1 Pyrazolyl derivatives in the form of drugs for treating acute or chronic neuronal regressions
04/15/2009EP1687257B1 Amino-substituted ethylamino beta2 adrenergic receptor agonists
04/15/2009EP1686997B1 Inhibitors of the mutant form of kit
04/15/2009EP1680099B1 Hdl-boosting combination therapy complexes
04/15/2009EP1667666B1 Pharmaceutical composition containing fenofibrate and method for the preparation thereof
04/15/2009EP1663989B1 CRYSTALLINE FORM OF BIS (E)-7- 4-(4-FLUOROPHENYL)-6-IS OPROPYL-2- METHYL(METHYLSULFONYL)AMINO PYRIMIDIN-5-YL&r sqb;(3R,5S)-3,5-DIHYDROXYHEPT-6 -ENOICACID CALCIUM SALT
04/15/2009EP1660091B1 Pyrimidine-2,4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
04/15/2009EP1646633B1 Beta-strand mimetics
04/15/2009EP1603533B1 Opioid delivery system
04/15/2009EP1572686B1 Anthranilic acid amide derivatives and their pharmaceutical use
04/15/2009EP1562628B1 Dc-sign blockers and their use for preventing or treating viral infections.
04/15/2009EP1543016B1 New 3-decladinosyl derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin a 9a,11-cyclic carbamates
04/15/2009EP1542668B1 Aripiprazole complex formulation and method
04/15/2009EP1539684B1 Benzenesulphonamides and process for their preparation
04/15/2009EP1531832B1 Therapeutic compositions for use in prophylaxis or treatment of diarrheas
04/15/2009EP1519731B1 Combination of azelastine and fluticasone
04/15/2009EP1480678B1 Treatment of ophthalmic disorders using urea and urea derivatives
04/15/2009EP1478360B1 Agents which interact with a serotonin transporter for the treatment of cancer
04/15/2009EP1458677B1 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
04/15/2009EP1446010B1 Stabilized azithromycin compositions
04/15/2009EP1435962A4 Treatment of type i diabetes
04/15/2009EP1432680B1 Spirocyclic 3-phenyl-3-substituted 4-ketolactams and 4-ketolactones
04/15/2009EP1423115B1 Antiangiogenic activity of nitrogen substituted thalidomide analogs
04/15/2009EP1419143B1 24-sulfur-substituted analogs of 1alpha,25-dihydroxy vitamin d3
04/15/2009EP1417307B1 Oligonucleotide compositions and their use to induce apoptosis
04/15/2009EP1414523B1 Use of a lactate salt for the treatment and prophylaxis of atherosclerosis
04/15/2009EP1406599B1 Cosmetic and dermatological preparations containing creatine for treating and actively preventing dry skin and other negative alterations of the physiological homeostasis of healthy skin
04/15/2009EP1385547B1 Antibody which binds to both lewis-y and lewis-b haptens, and its use for treating cancer
04/15/2009EP1378246B1 sPLA2 INHIBITORS FOR ARTERIOSCLEROSIS
04/15/2009EP1363635B1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
04/15/2009EP1326969B1 Improved system for regulation of transgene expression
04/15/2009EP1311532B1 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase
04/15/2009EP1297849B1 Remedial agent for optic nerve diseases
04/15/2009EP1267882B1 Prostaglandins for the treatment of eye disease caused by light irradiation like photoretinitis
04/15/2009EP1244648B1 Chemokine receptor binding heterocyclic compounds
04/15/2009EP1203007B1 Nucleic acid ligands to hepatocyte growth factor/scatter factor (hgf/sf) and its receptor c-met
04/15/2009EP1154999B1 Nitroxyderivatives having antiinflammatory, analgesic and antithrombotic activity
04/15/2009EP1151753B1 Preventive and therapeutic agents for arteriosclerosis
04/15/2009EP1098610B1 Biodegradable compositions for the controlled release of encapsulated substances
04/15/2009EP1043317B1 Pyridazine derivatives and medicaments containing them as active ingredient
04/15/2009EP1024805B1 Use of coumarin derivatives for the treatment of liver and pancreatic disorders
04/15/2009EP1012267B1 An antisense oligonucleotide preparation method
04/15/2009EP1003474B1 Method of treating dry eye disease with purinergic receptor agonists
04/15/2009CN101410518A dsRNA compositions and methods for treating HPV infection
04/15/2009CN101410414A Synergistic compositions for treating HIV-1
04/15/2009CN101410407A Substituted adenines and the uses thereof